Clinical Study Synopsis
|
|
- Madlyn Richard
- 5 years ago
- Views:
Transcription
1 Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before making any decisions on their treatment. Healthcare Professionals should always refer to the specific labeling information approved for the patient's country or region. Data in this document or on the related website should not be considered as prescribing advice. The study listed may include approved and non-approved formulations or treatment regimens. Data may differ from published or presented data and are a reflection of the limited information provided here. The results from a single trial need to be considered in the context of the totality of the available clinical research results for a drug. The results from a single study may not reflect the overall results for a drug. The following information is the property of Bayer HealthCare AG. Reproduction of all or part of this report is strictly prohibited without prior written permission from Bayer HealthCare AG. Commercial use of the information is only possible with the written permission of the proprietor and is subject to a license fee. Please note that the General Conditions of Use and the Privacy Statement of bayerhealthcare.com apply to the contents of this file.
2 Study Sponsor: Study Number: Study Phase: III Clinical Trial Results Synopsis Bayer Pharma, France Study Design Description NCT Official Study Title: A multinational, prospective, randomized, double-blind study to investigate the efficacy and safety of sequential intravenous/oral moxifloxacin in comparison to intravenous levofloxacin plus intravenous ceftriaxone followed by oral levofloxacin, in the treatment of patients with severe community-acquired pneumonia (CAP). Therapeutic Area: Anti-Infectives Test Product Name of Test Product: Name of Active Ingredient: Dose and Mode of Administration: Moxifloxacin (Avelox, BAY ) Moxifloxacin Hydrochloride Sequential intravenous (IV)/per os; orally (PO) moxifloxacin 400/400 mg once daily (od). Reference Therapy/Placebo Reference Therapy: IV levofloxacin plus IV ceftriaxone followed by oral levofloxacin Dose and Mode of Administration: Duration of Treatment: 7 to 14 days IV levofloxacin 500 mg bid (twice a day) plus IV ceftriaxone 2 g od followed by oral levofloxacin 500 mg bid. Studied period: Date of first subjects first visit: 08 JAN 2004 Premature Study Suspension / Termination: Substantial Study Protocol Amendments: Date of last subjects last visit: 08 JUL 2005 No Amendment no. 1 (dated 05 SEP 2003) specified that some health authorities considered intravenous clarithromycin unsafe for the treatment of very ill/elderly subjects due to QT interval prolongation problems with intravenous macrolides. The health authorities strongly advised the use of a comparator regimen that does not have cardiac safety issues in order to allow a clear safety assessment of moxifloxacin. Based on this recommendation, reference therapy of "IV ceftriaxone 2 g od plus IV clarithromycin followed by oral levofloxacin 500 mg bid" was changed to "IV ceftriaxone 2 g od plus IV levofloxacin 500 mg bid followed by oral levofloxacin 500 mg bid". Amendment no. 2 (dated 12 NOV 2003) specified the incorporation of an additional exclusion criterion for subjects with psychosis and/or schizophrenia. Amendment no. 3 (dated 20 FEB 2004) specified the incorporation of updated information to the "Warning/Precautions" section of the protocol. This Amendment also specified the incorporation of an additional exclusion criterion for subjects with pre-terminal failure Page 1 of 14
3 (creatinine clearance < 10 ml/min and subjects undergoing hemodialysis. Amendment no. 3 also specified the implementation of an external (unblinding) monitoring for drug accountability. Amendment no. 4 (dated 22 APR 2004) specified changes to the title of the protocol because of change of comparators. Amendment no. 5 (dated 03 JUN 2004) specified that hematology analyses would be performed by local laboratories for all visits, to avoid the long turn-around time between the sites and the central laboratory. Amendment no. 6 (dated 10 JAN 2005) specified modification in inclusion criteria. Subjects with fever and/or increase in white blood cell count or leucopenia could be recruited provided they met all other inclusion criteria, including radiological evidence of an infiltrate consistent with pneumonia. Study Centre(s): This study was conducted at 71 centers in 18 countries. Methodology: Subjects eligible for this study were stratified according to the severity of their illness to either Pneumonia Severity Index (PSI) Class III (Stratum 1) or PSI Classes IV to V (Stratum 2) according to the point scoring system of the prediction rule for assignment to PSI Classes I V in subjects with CAP. The number of subjects enrolled in Stratum 1 was not to exceed 50% of the overall study population. Subjects were maintained on IV therapy for the entire duration of the study if clinically indicated or switched to PO therapy after at least 3 full days of IV therapy. Clinical assessments were performed before therapy, during therapy on Days 3 to 5, and on the day-of-switch from IV to PO, at premature discontinuation/end-of-treatment (EOT), at the test-of-cure (TOC) Visit (4 to 14 days post therapy), and at follow-up (21to 28 days post therapy). The following signs and symptoms of pneumonia had to be documented: cough, dyspnea, sputum production, and quality, dullness to percussion, rigors, chills, rales, and pleuritic chest pain. Pre-therapy chest X-rays were systematically reviewed by a blinded committee and findings on chest examination were assessed for confirmation of the primary diagnosis. In subjects who required additional antimicrobial therapy, a clinical assessment was performed 5 to 7 days after completion of this therapy. This constituted the last assessment visit for these subjects. Indication/ Main Inclusion Criteria: A Critical Event Committee was set up to review all adverse events of cardiac nature. An independent clinical response evaluation Committee was responsible for the blinded evaluation of clinical response to study drugs. Indication Community-acquired pneumonia Main Inclusion criteria Adult subjects with CAP of PSI Class III, IV or V requiring hospitalization and initial parenteral antibiotic therapy. Page 2 of 14
4 Study Objectives: Overall: To determine the efficacy and safety of sequential IV/PO moxifloxacin monotherapy in comparison to a combination therapy with IV levofloxacin plus IV ceftriaxone followed by oral levofloxacin in the treatment of subjects admitted to hospital with severe CAP. Primary: To demonstrate that monotherapy with moxifloxacin IV/PO 400/400 mg once daily is not less effective than the comparator therapy based on clinical cure rate at the TOC visit. Evaluation Criteria: Secondary: To evaluate the safety including cardiac safety of monotherapy with moxifloxacin IV/PO 400/400 mg once daily in the treatment of subjects admitted to hospital with severe CAP. To assess the implications of each treatment group on healthcare resource utilization and overall costs associated with the treatment of CAP. Efficacy (Primary): Clinical response 4 to 14 days after completion of study treatment (TOC visit). \ Efficacy (Secondary): Clinical and bacteriological response on the day-of-switch from IV to oral therapy Clinical and bacteriological response on days 3 to 5 (if the dayof-switch was different from days 3 to 5) Clinical and bacteriological response at the EOT, i.e., on days 7 to 14 Bacteriological response at the TOC visit Mortality attributable to pneumonia at the TOC visit Clinical and bacteriological response 21 to 28 days after the EOT CAP symptoms course (at the different assessment visits) Economic analysis of study drug treatment on healthcare resource utilization and overall costs associated with the treatment of CAP Safety: Each subject was carefully monitored for adverse events. The following aspects of an adverse event were assessed: seriousness, severity, and relationship to study drug. Adverse events were coded using Medical Dictionary for Regulatory Activities (MedDRA). Moreover, safety assessments included results of physical examinations, vital signs data, and abnormal laboratory tests. Pharmacokinetics: Blood samples for determination of plasma moxifloxacin levels were obtained on Day 1 and Day 3, after the end of the moxifloxacin or ceftriaxone infusion, between the first and second post-infusion ECG recording. Page 3 of 14
5 Statistical Methods: Efficacy (Primary): The primary objective of this study was to reject the following null hypothesis: A 7 to 14 day sequential IV/PO treatment with moxifloxacin 400/400 mg od was more than 10% less effective than a 7 to 14 day treatment with IV levofloxacin 500 mg bid plus IV ceftriaxone 2 g od followed by oral levofloxacin 500 mg bid based on clinical success (= clinical cure) at the TOC Visit (4 to 14 days after the end of study drug treatment). The primary efficacy parameter was clinical response at the TOC Visit which was systematically and blindly assessed by the independent review board (Clinical Committee), and this constituted the primary efficacy analysis. For success rates, (i.e., cure rates at TOC), a 95% confidence interval (CI) of the difference of the 2 clinical success rates (Treatment Group "moxifloxacin" minus Treatment Group "comparator") was calculated using Mantel-Haenszel weights reflecting regions and strata. Non-inferiority of treatment with moxifloxacin was to be concluded if the lower limit of this CI was greater than -10% and the CI included 0. If, and only if the lower limit of this CI was greater than 0, the superiority of treatment with moxifloxacin was proven. Since the subjects were stratified with respect to the severity of disease, i.e., PSI Risk Class III vs PSI Risk Classes IV to V, a descriptive investigation was undertaken to determine the number of clinical cure and failure subjects within each of these strata for both treatment groups. Efficacy (Secondary): As secondary efficacy analyses, the clinical response assessed on the day-of-switch from IV to oral therapy, on days 3 to 5 (only if the day of the IV/PO switch was not days 3 to 5), at the EOT, at the follow-up, 21 to 28 days after completion of therapy, and the clinical response at TOC and follow-up in subjects with bacteriologically proven infection, was analyzed exploratively in the same way as the primary efficacy parameter. In those subjects with microbiological documentation, the clinical response at TOC was analyzed according to in-vitro susceptibility. At follow-up, analyses were performed on subjects who were assessed as "clinical cure" at the TOC Visit, but also on subjects with clinical failures at the TOC visit carried forward to the follow-up. Additionally, the bacteriological responses on the day-of-switch, on days 3 to 5 (if the day-of-switch was different from days 3 to 5), at the EOT, at the TOC visit (4 to 14 days after EOT) and follow-up were analyzed exploratively in the same way as the primary efficacy parameter based on the subgroup of microbiologically valid subjects. All efficacy analyses and tabulations of efficacy data were performed for the valid-per-protocol population (primary efficacy population) as well as for the intent-to-treat (ITT) population (secondary efficacy Page 4 of 14
6 population). The ITT populations corresponding to the subgroup of microbiologically valid subjects were subjects valid for the ITT analysis with causative organism(s) at enrollment. In the per protocol (PP) analyses of clinical and bacteriological response, the treatment comparisons were performed as "cure" vs "failure" (missing and indeterminate outcomes excluded from analysis), in the ITT analyses additionally to the analysis "cure" vs "failure", a comparison of "cure" vs "non-cure" was performed. Number of Subjects: Safety: In the safety analysis, special attention was paid to the nature and incidence of cardiac adverse events, including critical cardiac adverse events as blindly assessed by the Critical Event Committee (CEC), and their relationship to study drugs. Pharmacokinetics Descriptive statistics of moxifloxacin plasma concentrations were pooled according to time after end of infusion (safety population) and correlated with ECG data. A total of 748 subjects were enrolled in this study, 738 were randomized (371 in the moxifloxacin-treated group and 367 in the comparator-treated group). A total of 116 subjects withdrew early from the study (68 [18.3%] in the moxifloxacin-treated group and 48 [13.1%] in the comparatortreated group). Table 1 summarizes the disposition of subjects in this study. Table 1: Subjects included in each analysis population Study Results Results Summary Subject Disposition and Baseline Among moxifloxacin-treated subjects of the ITT/Safety population (n=368), 154 (41.8%) had a PSI score of II or III, 171 (46.5%), a PSI score of IV, and 43 (11.7%), a PSI score of V. Respective numbers in the comparator group (n=365) were 150 (41.1%), 172 (47.1%) and 43 (11.8%). Men subjects were predominant in the overall ITT population, i.e., 61.7% men vs 38.3% women. Mean age was 65.6 ± 16.7 years (range: 19 to 100 years) in the moxifloxacin-treated group versus (vs) 65.0 ± 17.1 years (range: 18 to 101 years) in the comparator-treated group. Mean BMI was 25.9 ± 5.2 kg/m 2 (range: 14.2 to 48.8 kg/m 2 ) in the moxifloxacin-treated group vs 26.0 ± 5.1 kg/m 2 (range: 12.6 to 50.8 kg/m 2 ) in the comparator-treated group. At study entry, 9.5% of the subjects in the moxifloxacin-treated group vs 10.4% in the comparator-treated group were admitted in an intensive care unit (ICU). Respectively, 5.4% of subjects in the moxifloxacin-treated group vs 5.2% in the Page 5 of 14
7 comparator treated group were ventilated at baseline. Partial pressure of arterial oxygen at room air was 60.6 ±11.4 mmhg vs 60.3 ± 12.9 in the moxifloxacin-treated group vs comparator-treated group respectively. Results Summary Efficacy Primary Efficacy Variables 187/291 (64.3%) moxifloxacin-treated subjects vs 185/278 (66.5%) comparator-treated subjects received at least 5 days of IV therapy. Table 2 summarizes treatment duration in the valid-per-protocol population according to Clinical Committee evaluation (PP1). Table 2: Duration of treatment for subjects valid in PP1 population (all regions) The clinical success rate at the TOC visit in the PP1 population was 86.9% in the moxifloxacin-treated group vs 89.9% in the comparator-treated group. Since the lower limit of the 95% CI for the difference in clinical success rates (-8.1%; 2.2%) was greater than -10%, moxifloxacin was not inferior to comparator in treating subjects with CAP of PSI Class III, IV or V. Table 3 summarizes results of clinical responses at the TOC visit in per protocol and ITT populations, based on Clinical Committee assessment. Table 3: Clinical success at the Test-of-Cure (PP1/ITT populations)- Clinical Committee assessment all regions Results of the ITT population and of the per protocol analyses based on clinical investigators assessment (PP2-87.8% moxifloxacin-treated group, 90.9% comparator-treated group; CI 95% [-8.0% - 2.0%]) were consistent with the primary efficacy analysis. Page 6 of 14
8 Table 4 summarizes results of the clinical responses at the TOC visit in different microbiologically documented subgroups. Table 4: Clinical success at Test-of-Cure (PP1 population in different microbiologically documented subjects subgroups) all regions Secondary Efficacy Variable The bacteriological success rate at the TOC Visit was 83.3% in the moxifloxacin-treated group and 85.3% in the comparator treated group for microbiologically valid subjects. Table 5 summarizes the bacteriological success rate at the TOC Visit in PP1 and intent-to-treat (ITT) populations. Page 7 of 14
9 Table 5: Bacteriological success at the Test-of-Cure from respiratory and/or blood cultures (PP1/ITT populations) all regions The bacteriological success rates against the key pathogens were similar between the two treatment groups. Table 6 summarizes the bacteriological success rate by causative organisms at the TOC visit in the per protocol microbiologically valid population (PP1/MBV). Table 6: Bacteriological success by causative organisms at the Test-of-Cure in respiratory and/or blood cultures (PP1/MBV a population) Results Summary Safety Table 7 shows the incidence rates of the various types of adverse events, premature discontinuation, hospitalization due to adverse events and death. Page 8 of 14
10 Table 7: Overview of adverse events and survival combined IV/PO administration of study drug (Safety population) In the valid for safety population, 208 subjects (57%) in the moxifloxacin-treated group and 193 subjects (53%) in the comparator-treated group presented with at least one treatment emergent adverse event. The most commonly occurring single adverse event was diarrhea (8% in the moxifloxacin-treated group vs 4% in the comparator-treated group; note that all data presentations are in the sequence moxifloxacin-treated group first followed by the comparator-treated group) followed by alanine transaminase (ALT) increased (3% vs 6%) and aspartate transaminase (AST) increased (3% vs 5%). Cardiac disorders were reported with the same incidence in both treatment groups (7%). Table 8 presents the overview of adverse events occurring under the IV route of treatment administration. Table 8: Overview of adverse events and survival occurring under the IV route of administration of study drug (Safety population) In the valid for safety population, 86 subjects (23%) in the moxifloxacin-treated group and 76 subjects (21%) in the comparator treated group had at least one drug-related treatmentemergent adverse event (investigator assessment). The most commonly occurring single adverse event was diarrhea (6% vs 2%) followed by ALT increased (2% vs 3%) and AST Page 9 of 14
11 increased (1% vs 3%). Most events of diarrhea in both groups were not diagnosed as Clostridium difficile-associated diarrhea. Drug-related cardiac adverse events were reported in less than 1% in the moxifloxacin-treated group vs 1% in the comparatortreated group. Table 9 summarizes the incidences of the most frequent (occurring in at least 1% of subjects) treatment-emergent adverse events by MedDRA system organ class and MedDRA event within system organ class. Table 9: Treatment emergent adverse events by MedDRA and adverse events occurring in at least 1% of subjects in any treatment group (Safety population) Table 10 summarizes the incidences of the most frequent (occurring in at least 1% of subjects) drug-related treatment-emergent adverse events by MedDRA system organ class and MedDRA event within system organ class. Page 10 of 14
12 Table 10: Drug-related treatment-emergent adverse events by MedDRA system organ class and MedDRA event within system organ class with incidence rate 1% in either treatment group (ITT/safety population). There were 40 deaths reported in the study. The death rate was 7% in the moxifloxacintreated group and 4% in the comparator-treated group (P = 0.11). A total of 12 of the 25 deaths with moxifloxacin and 5 of the 15 deaths with comparator occurred more than 7 days after the last dose of study drug. According to the Clinical Committee evaluation, the mortality rates attributable to pneumonia were 3% (12/368) in moxifloxacin-treated subjects and 2% (8/365) in comparator-treated subjects (in one subject of each group, the evaluation was not possible). All deaths attributable to pneumonia except one (in the comparator group) were in subjects with PSI Class IV or V. None of the deaths were considered related to study drug by the investigators. However, in one moxifloxacin treated subject, the cardiac arrest leading to death was assessed as being possibly related to study drug by the Critical Event Committee (for this subject, the Clinical Committee considered pneumonia to be the cause of death). The incidences of serious adverse events were 21% with moxifloxacin and 15% with comparator. Drug-related serious adverse events were reported in 5% and 3% of moxifloxacin-treated and comparator-treated subjects respectively. The most common drug related serious adverse events were electrocardiogram QT (corrected interval) prolongation: 2% vs 1%. These QT intervals corrected for heart rate (QTc) prolongations were not associated with any adverse events that could be considered a clinical surrogate for QTcprolongation related arrhythmias. The incidence of adverse events that resulted in premature discontinuation was low in both treatment groups (29 subjects, 8% moxifloxacin-treated group; 17 subjects, 5% comparatortreated group). Table 11 presents mean changes in QT interval according to Bazett s Formula (QTcB) and Fridericia s Formula (QTcF) for subjects who had paired valid ECGs. Page 11 of 14
13 Table 11: Mean and standard deviation of QT interval prolongation according to Bazett s Formula and Fridericia s Formula Results Summary Pharmacokinetics Table 12 summarizes the descriptive statistics of plasma concentrations. Table 12: Descriptive statistics of moxifloxacin plasma concentrations pooled according to time after end of infusion (Safety population) Page 12 of 14
14 Figure 1: Plasma concentration vs QTc interval changes from Baseline to Day 1 Population: Subjects valid for PK with valid Baseline, Day 1 and Day 3 ECGs, all regions, Day 1 Figure 2: Plasma concentration vs QTc interval changes from Baseline to Day 3 Population: Subjects valid for PK with valid Baseline, Day 1 and Day 3 ECGs, all regions, Day 3 The pharmacokinetics in this subject population was comparable to those obtained previously in subjects with CAP and in healthy subjects. Peak concentrations were similar to those found in Phase I studies (based on historic comparison). Analysis of the peak concentrations with Page 13 of 14
15 respect to age and sex were also in line with previous findings indicating that there was no clinically relevant age and gender effect in this subject population. No correlation was seen between moxifloxacin concentrations and QTc absolute changes, with the exception of the valid baseline, day 1, and day 3 ECG when QTcB changes from baseline observed on day 3 were tested for correlation with plasma concentrations (P = 0.034) (Figure 1 and Figure 2). Conclusion(s) In this study, the study population was adequately selected with over 60% of subjects having a PSI risk Class of Class IV or V. The mean duration of IV therapy was 6 days. The sequential IV to oral moxifloxacin regimen was demonstrated to be non-inferior to a combination regimen of levofloxacin plus ceftriaxone in the management of subjects with severe CAP. The clinical cure rate at the TOC visit in the primary efficacy analysis was 86.9% for moxifloxacin monotherapy and 89.9% for the ceftriaxone plus levofloxacin combination (95% CI: -8.1% to 2.2%). The non-inferiority of moxifloxacin was also demonstrated in the subgroups of subjects in PSI Class IV or V. Secondary efficacy analyses were consistent with the results of the primary analysis. Both sequential IV/oral moxifloxacin and the comparator regimen were well tolerated. The adverse events in moxifloxacin treated and comparator-treated subjects were generally similar and were typical of the events to be expected in subjects with severe CAP. Although moxifloxacin produced an - expected - QTc prolongation, an analysis of cardiac events and events considered surrogates of arrhythmia did not detect a proarrhythmic effect of moxifloxacin in this high risk population. There was no evidence of a drug-related death in either treatment group (with the exception of one moxifloxacin-treated subject for whom the Critical Event Committee assessed the event with fatal outcome as possibly related to study drug). Although the mortality rate was slightly higher in the moxifloxacin-treated group, it was not associated with a drug-related toxicity. There were no clinically significant differences between the treatment groups for clinical laboratory test abnormalities. In summary, this study demonstrated that sequential therapy with once daily IV/oral moxifloxacin was not less effective than a twice daily application of the combination therapy of high dose of levofloxacin and ceftriaxone in the treatment of hospitalized subjects requiring initial IV therapy for community-acquired pneumonia. Moxifloxacin was effective in the most severe cases including bacteremic subjects and subjects with a Pneumonia Severity Index Class IV to V. It demonstrated to have an acceptable safety profile. Publication(s): Date Created or Date Last Updated: Torres A, Garau J, Arvis P, Carlet J, Choudhri S, Kureishi A, Le Berre MA, Lode H, Winter J, Read RC; MOTIV (MOxifloxacin Treatment IV) Study Group. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial. Clin Infect Dis May 15;46(10): FEB 2012 Date of Clinical Study Report: 14 SEP 2006 Page 14 of 14
16 Appendix to Clinical Study Synopsis Product Identification Information Product Type Drug US Brand/Trade Name(s) Avelox [Oral formulation] Brand/Trade Name(s) ex-us Generic Name Main Product Company Code Other Company Code(s) Chemical Description Other Product Aliases Avelox Avalox Actira Octegra Izilox Havelox Megaxin Proflox Promira Moxifloxacin BAY n/a 1-Cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)- octahydro-6h-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4- dihydroquinoline-3-carboxylic acid hydrochloride. n/a Date of last Update/Change: 19 August 2010
Period of study: 12 Nov 2002 to 08 Apr 2004 (first subject s first visit to last subject s last visit)
Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website and is provided for patients and healthcare professionals to increase the transparency of Bayer's
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationmoxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering
moxifloxacin intravenous, 400mg/250mL, solution for infusion (Avelox ) SMC No. (650/10) Bayer Schering 05 November 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationUniversité catholique de Louvain, Louvain Drug Research Institute, Brussels, Belgium. Bayer Santé SAS, Loos, France
Communicating Comprehensive Safety Data Gained from Clinical Trials to the Scientific Community: Opportunities and Difficulties from an Example with Moxifloxacin P.M. Tulkens, 1 P. Arvis, 2 F. Kruesmann,
More informationLefamulin Evaluation Against Pneumonia (LEAP 1) Phase 3 Topline Results. September 18, 2017
Lefamulin Evaluation Against Pneumonia (LEAP 1) Phase 3 Topline Results September 18, 2017 Safe Harbor and Disclaimer Any statements in this presentation about future expectations, plans and prospects
More informationSuitability of Antibiotic Treatment for CAP (CAPTIME) The duration of antibiotic treatment in community acquired pneumonia (CAP)
STUDY PROTOCOL Suitability of Antibiotic Treatment for CAP (CAPTIME) Purpose The duration of antibiotic treatment in community acquired pneumonia (CAP) lasts about 9 10 days, and is determined empirically.
More informationScottish Medicines Consortium
Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationSynopsis. Takeda Pharmaceutical Company Limited Name of the finished product UNISIA Combination Tablets LD, UNISIA Combination Tablets
Synopsis Name of the sponsor Takeda Pharmaceutical Company Limited Name of the finished product UNISIA Combination Tablets LD, UNISIA Combination Tablets Name of active ingredient Title of the study Study
More informationGUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS
Version 3.1 GUIDELINES FOR THE MANAGEMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS Date ratified June 2008 Updated March 2009 Review date June 2010 Ratified by Authors Consultation Evidence base Changes
More informationCLINICAL PROTOCOL FOR COMMUNITY ACQUIRED PNEUMONIA. SCOPE: Western Australia. CORB score equal or above 1. All criteria must be met:
CLINICAL PROTOCOL F COMMUNITY ACQUIRED PNEUMONIA SCOPE: Western Australia All criteria must be met: Inclusion Criteria Exclusion Criteria CB score equal or above 1. Mild/moderate pneumonia confirmed by
More informationAntibiotics use and Considerations: Calves and Heifers CLASSIFICATION OF CALVES. Danielle A. Mzyk TITLE 24 PT. ARIAL BOLD ALL CAPS
CALF AND HEIFER CONGRESS - 2016 Antibiotics use and Considerations: Calves and Heifers Danielle A. Mzyk TITLE 24 PT. ARIAL BOLD ALL CAPS Today s Presentation Classification of Calves Define Preruminant
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY
More informationPneumonia considerations Galia Rahav Infectious diseases unit Sheba medical center
Pneumonia considerations 2017 Galia Rahav Infectious diseases unit Sheba medical center Sir William Osler (1849 1919) "Father of modern medicine Pneumonia: The old man's friend The captain of the men of
More informationANNEX III AMENDMENTS TO THE SUMMARY OF PRODUCT CHARACTERISTICS AND PACKAGE LEAFLET
ANNEX III AMENDMENTS TO THE SUMMARY OF PRODUCT CHARACTERISTICS AND PACKAGE LEAFLET 1 AMENDMENTS TO BE INCLUDED IN THE RELEVANT SECTIONS OF THE SUMMARY OF PRODUCT CHARACTERISTICS FOR MOXIFLOXACIN CONTAINING
More informationAZITHROMYCIN, DOXYCYCLINE, AND FLUOROQUINOLONES
AZITHROMYCIN, DOXYCYCLINE, AND FLUOROQUINOLONES Update in Medicine and Primary Care Whitney R. Buckel, PharmD, BCPS-AQ ID System Antimicrobial Stewardship Pharmacist Manager OBJECTIVES 1. List three antibiotics
More informationAntibacterial Resistance: Research Efforts. Henry F. Chambers, MD Professor of Medicine University of California San Francisco
Antibacterial Resistance: Research Efforts Henry F. Chambers, MD Professor of Medicine University of California San Francisco Resistance Resistance Dose-Response Curve Antibiotic Exposure Anti-Resistance
More informationObjectives 4/26/2017. Co-Investigators Sadie Giuliani, PharmD, BCPS Claude Tonnerre, MD Jayme Hartzell, PharmD, MS, BCPS
IMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP) Lucas Schonsberg, PharmD PGY-1 Pharmacy Practice Resident Providence St. Patrick Hospital Missoula,
More information17 th Club Phase 1 Annual Meeting April 5, Pierre Maison-Blanche Hopital Bichat, Paris, France
Practical Issues for the clinical evaluation of QT/QTc interval prolongation 17 th Club Phase 1 Annual Meeting April 5, 2018 Pierre Maison-Blanche Hopital Bichat, Paris, France Disclosure Chiesi Pharmaceuticals
More informationScottish Medicines Consortium
Scottish Medicines Consortium daptomycin 350mg powder for concentrate for solution for infusion (Cubicin ) Chiron Corporation Limited No. (248/06) 10 March 2006 The Scottish Medicines Consortium (SMC)
More informationPhase III Clinical Trial of Moxifloxacin Hydrochloride in the Treatment of Acute Exacerbations of Chronic Bronchitis in Comparison with Azithromycin
ORIGINAL ARTICLE JIACM 2002; 3(4): 360-6 Phase III Clinical Trial of Moxifloxacin Hydrochloride in the Treatment of Acute Exacerbations of Chronic Bronchitis in Comparison with Azithromycin SH Talib*,
More informationClinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: HIM*, Medicaid
Clinical Policy: (Zyvox) Reference Number: CP.PMN.27 Effective Date: 09.01.06 Last Review Date: 02.19 Line of Business: HIM*, Medicaid Coding Implications Revision Log See Important Reminder at the end
More informationAntimicrobial Stewardship
Antimicrobial Stewardship Report: 11 th August 2016 Issue: As part of ensuring compliance with the National Safety and Quality Health Service Standards (NSQHS), Yea & District Memorial Hospital is required
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sun, 10 Mar 2019 06:52:14 GMT) CTRI Number Last Modified On 29/07/2016 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
More informationTreatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days
Treatment Duration for Uncomplicated Community-Acquired Pneumonia: The Evidence in Support of 5 Days Executive Summary National consensus guidelines created jointly by the Infectious Diseases Society of
More informationUPDATE ON ANTIMICROBIAL STEWARDSHIP REGULATIONS AND IMPLEMENTATION OF AN AMS PROGRAM
UPDATE ON ANTIMICROBIAL STEWARDSHIP REGULATIONS AND IMPLEMENTATION OF AN AMS PROGRAM Diane Rhee, Pharm.D. Associate Professor of Pharmacy Practice Roseman University of Health Sciences Chair, Valley Health
More informationDevelopment of Drugs for HAP-VAP. Robert Fromtling, MD
Development of Drugs for HAP-VAP Robert Fromtling, MD Hospital-Acquired & Ventilator- Associated Pneumonia (HAP-VAP) The EMA 2015 roadmap recognizes the need for new antibiotics New drugs for HAP-VAP are
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form
Last Updated: Version 3.2a NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form Organization Set Measure ID#
More informationResearch & Reviews: Journal of Hospital and Clinical Pharmacy
Research & Reviews: Journal of Hospital and Clinical Pharmacy Empiric Antibiotic Prescribing For Community Acquired Pneumonia and Patient Characteristics Associated with Broad Spectrum Antibiotic Use Mirza
More informationCritical Appraisal Topic. Antibiotic Duration in Acute Otitis Media in Children. Carissa Schatz, BSN, RN, FNP-s. University of Mary
Running head: ANTIBIOTIC DURATION IN AOM 1 Critical Appraisal Topic Antibiotic Duration in Acute Otitis Media in Children Carissa Schatz, BSN, RN, FNP-s University of Mary 2 Evidence-Based Practice: Critical
More informationMeasure Information Form
Release Notes: Measure Information Form Version 3.0b **NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE** Measure Set: Pneumonia (PN) Performance Measure Identifier: Measure Information Form
More informationGuideline on the conduct of efficacy studies for intramammary products for use in cattle
1 2 3 18 October 2013 EMEA/CVMP/EWP/141272/2011 Committee for Medicinal products for Veterinary Use (CVMP) 4 5 6 Guideline on the conduct of efficacy studies for intramammary products for use in cattle
More informationESISTONO LE HCAP? Francesco Blasi. Sezione Medicina Respiratoria Dipartimento Toraco Polmonare e Cardiocircolatorio Università degli Studi di Milano
ESISTONO LE HCAP? Francesco Blasi Sezione Medicina Respiratoria Dipartimento Toraco Polmonare e Cardiocircolatorio Università degli Studi di Milano Community-acquired pneumonia (CAP): Management issues
More informationLefamulin: a novel pleuromutilin antibiotic class George Dimopoulos MD, PhD, FCCP, FCCM, FECMM
: a novel pleuromutilin antibiotic class George Dimopoulos MD, PhD, FCCP, FCCM, FECMM Department of Critical Care, University Hospital ATTIKON National and Kapodistrian University of Athens, Medical School
More informationECHO: Management of URIs. Charles Krasner, M.D. Sierra NV Veterans Affairs Hospital University of NV, Reno School of Medicine October 16, 2018
ECHO: Management of URIs Charles Krasner, M.D. Sierra NV Veterans Affairs Hospital University of NV, Reno School of Medicine October 16, 2018 Infectious causes of URIs change over time Most ARIs are viral
More informationLifting the lid off CAP guidelines
Lifting the lid off CAP guidelines Dr. Andrew M. Morris September 5, 2007 12:00-13:00 web.mac.com/idologist Objectives 1. To review the epidemiology of community-acquired pneumonia (CAP) 2. To explore
More informationOptimizing Antimicrobial Stewardship Activities Based on Institutional Resources
Optimizing Antimicrobial Stewardship Activities Based on Institutional Resources Andrew Hunter, PharmD, BCPS Infectious Diseases Clinical Pharmacy Specialist Michael E. DeBakey VA Medical Center Andrew.hunter@va.gov
More informationCommunity-acquired pneumonia: Time to place a CAP on length of treatment?
LOGIN TO LEARN: An Engaging and Interactive Journal Club for Pharmacists and Students Community-acquired pneumonia: Time to place a CAP on length of treatment? Jennifer Ball, PharmD Learning Objectives
More informationPharmacokinetics. Absorption of doxycycline is not significantly affected by milk or food, but coadministration of antacids or mineral supplements
Pharmacokinetics. Absorption of doxycycline is not significantly affected by milk or food, but coadministration of antacids or mineral supplements should be avoided. PDR Drug Summaries are concise point-of-care
More informationIMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP)
IMPLEMENTATION AND ASSESSMENT OF A GUIDELINE-BASED TREATMENT ALGORITHM FOR COMMUNITY-ACQUIRED PNEUMONIA (CAP) Lucas Schonsberg, PharmD PGY-1 Pharmacy Practice Resident Providence St. Patrick Hospital Missoula,
More informationMoxifloxacin (as hydrochloride) 400 mg Tablets WHOPAR part 6 November 2017 (Hetero Labs Limited), TB 315
This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1
More informationSrirupa Das, Associate Director, Medical Affairs, Tushar Fegade, Manager, Clinical Research Abbott Healthcare Private Limited, Mumbai.
Indian Medical Gazette JUNE 2015 225 Comparative A Randomized, Open Label, Prospective, Comparative Evaluating the Efficacy and Safety of Fixed Dose Combination of Cefpodoxime 200 Mg + Clavulanic Acid
More informationNewsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017
Newsflash: Hospital Medicine JOHN C. CHRISTENSEN, MD FACP AMERICAN COLLEGE OF PHYSICIANS, UTAH CHAPTER SCIENTIFIC MEETING FEBRUARY 10, 2017 Newsflash: Fluoroquinolones Newsflash: Fluoroquinolones Don t
More information11/22/2016. Antimicrobial Stewardship Update Disclosures. Outline. No conflicts of interest to disclose
Antimicrobial Stewardship Update 2016 APIC-CI Conference November 17 th, 2016 Jay R. McDonald, MD Chief, ID Section VA St. Louis Health Care System Assistant Professor of medicine Washington University
More informationInappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012
Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationDuration of antibiotic therapy:
Duration of antibiotic therapy: How low can you go? Thomas Holland, MD Hilton Head, SC July 2017 Disclosures Consulting: The Medicines Company, Basilea Pharmaceutica Adjudication committee: Achaogen Grant
More informationHealthcare-associated Infections and Antimicrobial Use Prevalence Survey
Healthcare-associated Infections and Antimicrobial Use Prevalence Survey Shamima Sharmin, M.B.B.S., MSc, MPH Emerging Infections Program New Mexico Department of Health Agenda Recognize healthcare-associated
More informationCombination vs Monotherapy for Gram Negative Septic Shock
Combination vs Monotherapy for Gram Negative Septic Shock Critical Care Canada Forum November 8, 2018 Michael Klompas MD, MPH, FIDSA, FSHEA Professor, Harvard Medical School Hospital Epidemiologist, Brigham
More informationPropofol vs Dexmedetomidine
Propofol vs Dexmedetomidine A highlight of similarities & differences Lama Nazer, PharmD, BCPS Critical Care Clinical Pharmacy Specialist King Hussein Cancer Center Outline Highlight similarities and differences
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Nuzyra) Reference Number: CP.PMN.## Effective Date: 11.20.18 Last Review Date: 02.19 Line of Business: Commercial, TBD HIM*, Medicaid Coding Implications Revision Log See Important Reminder
More informationGuidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults)
Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Community Acquired Pneumonia Community Acquired Pneumonia 1) Is it pneumonia? ie new symptoms and signs of
More informationMHA/OHA HIIN Antibiotic Stewardship/MDRO Collaborative
MHA/OHA HIIN Antibiotic Stewardship/MDRO Collaborative Place picture here Nov. 14, 2017 Reminders For best sound quality, dial in at 1-800-791-2345 and enter code 11076 Please use the chat box to ask questions!
More informationPharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection Quenzer R W, Pettit K G, Arnold R J, Kaniecki D J
Pharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection Quenzer R W, Pettit K G, Arnold R J, Kaniecki D J Record Status This is a critical abstract of an economic evaluation
More informationClinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: Oregon Health Plan
Clinical Policy: (Zyvox) Reference Number: CP.PMN.27 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end of this policy
More informationCost high. acceptable. worst. best. acceptable. Cost low
Key words I Effect low worst acceptable Cost high Cost low acceptable best Effect high Fig. 1. Cost-Effectiveness. The best case is low cost and high efficacy. The acceptable cases are low cost and efficacy
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationAmikacin Inhale shows promising results in Phase II Study
Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Amikacin Inhale shows promising results in Phase II Study Bayer together with Nektar Therapeutics present preliminary
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #407: Appropriate Treatment of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Bacteremia National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES:
More informationCurricular Components for Infectious Diseases EPA
Curricular Components for Infectious Diseases EPA 1. EPA Title Promoting antimicrobial stewardship based on microbiological principles 2. Description of the A key role for subspecialists is to utilize
More informationAuthor - Dr. Josie Traub-Dargatz
Author - Dr. Josie Traub-Dargatz Dr. Josie Traub-Dargatz is a professor of equine medicine at Colorado State University (CSU) College of Veterinary Medicine and Biomedical Sciences. She began her veterinary
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
Antibiotic treatment and monitoring for suspected or confirmed early-onset neonatal infection bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to
More informationGuidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults)
Guidelines for the Initiation of Empirical Antibiotic therapy in Respiratory Disease (Adults) Community Acquired Community Acquired 1) Is it pneumonia? ie new symptoms and signs of a lower respiratory
More informationAn audit of the quality of antimicrobial prescribing
An audit of the quality of antimicrobial prescribing Rakhee Patel, Antimicrobial Pharmacist Alison Williams, Antimicrobial Technician & Dr Armando Gonzalez-Ruiz May 2011 ICE Score 2 Introduction & Aims
More informationStudy population The target population for the model were hospitalised patients with cellulitis.
Comparison of linezolid with oxacillin or vancomycin in the empiric treatment of cellulitis in US hospitals Vinken A G, Li J Z, Balan D A, Rittenhouse B E, Willke R J, Goodman C Record Status This is a
More informationOutpatient parenteral antimicrobial treatment. Which antibiotics can be used?
Outpatient parenteral antimicrobial treatment Which antibiotics can be used? Franky Buyle SBIMC-BVIKM March 30th 2017 Brussels Pharmacy Multidisciplinary Infection Team Ghent University Hospital, Belgium
More informationTreatment for NTM: when how.and what next? Pr Claire Andréjak Respiratory and ICU Department University hospital, Amiens, France
Treatment for NTM: when how.and what next? Pr Claire Andréjak Respiratory and ICU Department University hospital, Amiens, France First step = To diagnose NTM disease One NTM positive sample NTM disease
More informationAntimicrobial Stewardship in the Long Term Care and Outpatient Settings. Carlos Reyes Sacin, MD, AAHIVS
Antimicrobial Stewardship in the Long Term Care and Outpatient Settings Carlos Reyes Sacin, MD, AAHIVS Disclosure Speaker and consultant in HIV medicine for Gilead and Jansen Pharmaceuticals Objectives
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.HNMC.24 Effective Date: 07.01.17 Last Review Date: 02.18 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy for important
More informationDeveloping Well-Differentiated Antibiotics. June 2017 Mark Hahn Chief Financial Officer
Developing Well-Differentiated Antibiotics June 2017 Mark Hahn Chief Financial Officer Forward Looking Statements This presentation contains forward-looking statements regarding future events. These statements
More informationPneumonia Antibiotic Guidance for Adults PAGL Inclusion Approved at January 2017 PGC
Pneumonia Antibiotic Guidance for Adults PAGL Inclusion Approved at January 2017 PGC APPROVED BY: Policy and Guidelines Committee TRUST REFERENCE: B9/2009 AWP Ref: AWP61 Date (approved): July 2008 REVIEW
More informationClinical Practice Standard
Clinical Practice Standard 1-20-6-1-010 TITLE: INTRAVENOUS TO ORAL CONVERSION FOR ANTIMICROBIALS A printed copy of this document may not reflect the current, electronic version on OurNH. APPLICABILITY:
More informationLyme disease: diagnosis and management
National Institute for Health and Care Excellence Final Lyme disease: diagnosis and management [D] Evidence review for the management of erythema migrans NICE guideline 95 Evidence review April 2018 Final
More informationPromoting Appropriate Antimicrobial Prescribing in Secondary Care
Promoting Appropriate Antimicrobial Prescribing in Secondary Care Stuart Brown Healthcare Acquired Infection and Antimicrobial Resistance Project Lead NHS England March 2015 Introduction Background ESPAUR
More informationCHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
CHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY Antibiotics One of the most commonly used group of drugs In USA 23
More informationACUTE EXACERBATIONS of COPD (AE-COPD) : The Belgian perspective
ACUTE EXACERBATIONS of COPD (AE-COPD) : The Belgian perspective Antwerpen 8 november 2002 Yvan Valcke MD PhD AZ Maria Middelares Sint-Niklaas ACUTE EXACERBATIONS of COPD (AE-COPD) Treatment of AECB Role
More informationComparative efficacy of DRAXXIN or Nuflor for the treatment of undifferentiated bovine respiratory disease in feeder cattle
Treatment Study DRAXXIN vs. Nuflor July 2005 Comparative efficacy of DRAXXIN or Nuflor for the treatment of undifferentiated bovine respiratory disease in feeder cattle Pfizer Animal Health, New York,
More informationAntimicrobial Stewardship 101
Antimicrobial Stewardship 101 Betty P. Lee, Pharm.D. Pediatric Infectious Disease/Antimicrobial Stewardship Pharmacist Lucile Packard Children s Hospital Stanford Disclosure I have no actual or potential
More informationLe infezioni di cute e tessuti molli
Le infezioni di cute e tessuti molli SCELTE e STRATEGIE TERAPEUTICHE Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Treatment of complicated skin and skin structure infections
More informationStudy of First Line Antibiotics in Lower Respiratory Tract Infections in Children
IOSR Journal of Pharmacy and Biological Sciences (IOSR-JPBS) e-issn:2278-3008, p-issn:239-7676. Volume 2, Issue 4 Ver. VI (Jul Aug 207), PP 47-55 www.iosrjournals.org Study of First Line Antibiotics in
More informationAntimicrobial Stewardship in Ambulatory Care
Antimicrobial Stewardship in Ambulatory Care Nila Suntharam, M.D. May 5, 2017 Dr. Suntharam indicated no potential conflict of interest to this presentation. She does not intend to discuss any unapproved/investigative
More informationPOINT PREVALENCE SURVEY A tool for antibiotic stewardship in hospitals. Koen Magerman Working group Hospital Medicine
POINT PREVALENCE SURVEY A tool for antibiotic stewardship in hospitals Koen Magerman Working group Hospital Medicine Background Strategic plan By means of a point prevalence survey and internal audits
More informationPharmacist Coordinated Antimicrobial Therapy: OPAT and Transitions of Care
Pharmacist Coordinated Antimicrobial Therapy: OPAT and Transitions of Care Jennifer McCann, PharmD, BCCCP State Director of Clinical Pharmacy Services St. Vincent Health Indiana Conflicts of Interest No
More informationDoxycycline for strep pneumonia
Doxycycline for strep pneumonia Antibiotic Levofloxacin (Levaquin) 750 mg, 500 mg for the treatment of respiratory, skin, and urinary tract infections, user reviews and ratings. 14-12-1995 John G. Bartlett,
More information2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority
Quality ID #407: Appropriate Treatment of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Bacteremia National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Healthcare Associated
More informationOptimize Durations of Antimicrobial Therapy
Optimize Durations of Antimicrobial Therapy Evidence & Application Jill Cowper, Pharm.D. Division Infectious Diseases Pharmacist Parallon Supply Chain Solutions Richmond, VA P: 607 221 5101 jill.butterfield@parallon.com
More informationVI.B.2 Elements for a public summary. VI.B.2.1 Overview of disease epidemiology
VI.B.2 Elements for a public summary VI.B.2.1 Overview of disease epidemiology [Moxifloxacin] 400mg/250ml solution for infusion Moxifloxacin is a fluoroquinolone antibiotic with a broad spectrum of activity
More informationAntimicrobial Stewardship Programs The Same, but Different. Sara Nausheen, MD Kevin Kern, PharmD
Antimicrobial Stewardship Programs The Same, but Different Sara Nausheen, MD Kevin Kern, PharmD Antimicrobial Stewardship Programs The Same, but Different Objectives: Outline the overall function of an
More informationAntimicrobial Stewardship Strategy: Intravenous to oral conversion
Antimicrobial Stewardship Strategy: Intravenous to oral conversion Promoting the use of oral antimicrobial agents instead of intravenous administration when clinically indicated. Description This is an
More informationThe pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens
The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels,
More informationApril 25, 2018 Edited by: Gregory K. Perry, PharmD, BCPS-AQID
VOLUME FOUR; ISSUE 4 April 25, 2018 Edited by: Gregory K. Perry, PharmD, BCPS-AQID InPHARMation Pharmacy and Therapeutics Committee Update April 25 th, 2018 Meeting The Pharmacy and Therapeutics Committee
More informationCommunity Acquired Pneumonia: An Update on Guidelines
Community Acquired Pneumonia: An Update on Guidelines Claudia Summa, BScPhm Pharmacy Resident September 12, 2006 Objectives To give a brief description of the pathophysiology of community acquired pneumonia
More informationUnderstand the application of Antibiotic Stewardship regulations in LTC. Understand past barriers to antibiotic management concepts
Objectives Understand the application of Antibiotic Stewardship regulations in LTC Understand past barriers to antibiotic management concepts Understand benefits of adoption of antibiotic stewardship regulations
More informationEvaluating the Role of MRSA Nasal Swabs
Evaluating the Role of MRSA Nasal Swabs Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds February 28, 2017 2016 MFMER slide-1 Objectives Identify the pathophysiology of MRSA nasal colonization
More informationAntibiotic Stewardship: The Facility Role and Implementation. Tim Cozad, LPN, Lead LTC Health Facilities Surveyor
Antibiotic Stewardship: The Facility Role and Implementation Tim Cozad, LPN, Lead LTC Health Facilities Surveyor Phase II CMS Regulatory Changes Current information available includes: New Survey Process
More informationDATA COLLECTION SECTION BY FRONTLINE TEAM. Patient Identifier/ Medical Record number (for facility use only)
Assessment of Appropriateness of ICU Antibiotics (Patient Level Sheet) **Note this is intended for internal purposes only. Please do not return to PQC.** For this assessment, inappropriate antibiotic use
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationEPAR type II variation for Metacam
23 June 2011 EMA/674662/2011 International Non-proprietary Name: Meloxicam Procedure No. EMEA/V/C/033/II/084 EU/2/97/004/026, 33-34 Scope: Type II Addition of indication for cats Page 1/6 Table of contents
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationAssessment of empirical antibiotic therapy in a tertiary-care hospital: An observational descriptive study
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 15, Issue 9 Ver. VI (September). 2016), PP 118-124 www.iosrjournals.org Assessment of empirical antibiotic
More information